PCA
PTCT icon

Pallas Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Pallas Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
3,222
+132
+4% +$9.53K 0.01% 785
2026
Q1 		$211K Sell
3,090
-184
-6% -$13K 0.01% 752
2025
Q4 		$249K Buy
+3,274
New +$238K 0.01% 750
2025
Q3 		– Sell
-4,203
Closed -$205K – 937
2025
Q2 		$205K Sell
4,203
-2,722
-39% -$129K 0.01% 762
2025
Q1 		$353K Buy
+6,925
New +$346K 0.01% 560

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Pallas Capital Advisors's PTCT Position: Q2 2026 in Review

Pallas Capital Advisors increased its PTC Therapeutics (PTCT) stake by 4.3% in Q2 2026, buying an estimated $9.53K and bringing the position to 3,222 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #785.

Pallas Capital Advisors first reported a position in PTCT in Q1 2025 and has held it in 5 quarters since. The position peaked at $353K in Q1 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Pallas Capital Advisors held 3,222 shares of PTC Therapeutics worth $263K as of Q2 2026.
  • Pallas Capital Advisors bought 132 PTC Therapeutics shares in Q2 2026, an estimated $9.53K.
  • PTC Therapeutics made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #785 holding.
  • Pallas Capital Advisors first reported a position in PTC Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Pallas Capital Advisors's PTC Therapeutics position peaked at $353K in Q1 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.